Patents Represented by Attorney Choate, Hall & Stewart
  • Patent number: 8349356
    Abstract: The present invention provides hemostatic compositions comprising components of the flowers of pharmaceutical chamomile (Chamomilla recutita) and the leaves of dioecious nettle (Urtica dioica). Further inclusion of a biocompatible polymeric base, particularly an alignate, generates a composition with excellent and broad spectrum hemostatic capabilities, with concurrent antiseptic and anti-inflammatory properties. The invention further provides methods of using the inventive compositions in to reduce or stop bleeding, as well as a variety of apparatuses useful in hemostatic contexts that incorporate the inventive compositions. In one particular embodiment, the invention provides hemostatic dressings in which a polymeric layer incorporating chamomile and nettle components is applied to a textile or fabric material, for example a non-woven viscose.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: January 8, 2013
    Inventors: Natalia Dmitrievna Oltarshevskaya, Larisa Borisovna Savilova, German Evseevich Krichevsky
  • Patent number: 8350045
    Abstract: A process for preparation of E-isomer of 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene of Formula-I, and acid addition salts thereof, said process comprising; dehydrating 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinopropan-1-ol of Formula III followed by adding a base solution to obtain a mixture of E and Z isomers of 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene, and washing said mixture of E and Z isomers of 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene with water to dissolve Z isomer and to obtain E-isomer of 1-(4-methylphenyl)-1-(2-pyridyl)-3-pyrrolidinoprop-1-ene of Formula I, which is substantially free from Z isomer.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: January 8, 2013
    Assignee: Hikal Limited
    Inventors: Rajender Pershad Gupta, Veerabhadra Swamy Hiremath, Raghavendra Arekal Vasanna, Vasantha Gowda Nekkilar
  • Patent number: 8350073
    Abstract: The present invention provides methods for the synthesis of catalysts and precursors thereof. Methods of the invention may comprise combining a catalyst precursor and at least one ligand to generate a catalytically active species, often under mild conditions and in high yields. In some cases, a wide variety of catalysts may be synthesized from a single catalyst precursor. Methods of the invention may also include the preparation of catalysts which, under reaction conditions known in the art, may have been difficult or impossible to prepare and/or isolate due to, for example, steric crowding at the metal center. The present invention also provides catalyst compositions, and precursors thereof, which may be useful in various chemical reactions including olefin metathesis. In some cases, methods of the invention may reduce the number of synthetic and purification steps required to produce catalysts and/or other reaction products, as well as reducing time, cost, and waste production.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: January 8, 2013
    Assignee: Massachusetts Institute of Technology
    Inventors: Adam S. Hock, Richard R. Schrock
  • Patent number: 8343751
    Abstract: The present invention relates to the use of F4+ non-pathogenic Escherichia coli strains to promote growth in an animal. The present invention also relates to the use of such strains to homogenize growth among a herd of animals. More specifically, the animal(s) of interest in the present invention are those wherein growth promotion or growth homogenization are desired goals, such as animals reared for meat production. The present invention further relates to a method for promoting growth of an animal as well as a method for homogenizing growth among a herd of animals.
    Type: Grant
    Filed: July 8, 2011
    Date of Patent: January 1, 2013
    Assignee: Valorisation—Recherche, Limited Partnership
    Inventors: Eric Nadeau, John Morris Fairbrother
  • Patent number: 8338439
    Abstract: The present invention provides 2,4-disubstituted pyrimidine compounds useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same. In some embodiments, the present invention provides a compound of formula I-a or I-b: wherein each of Ring A, Ring B, W1, W2, Ry, Rv, Rx, m, p, and R1 is described herein.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: December 25, 2012
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Russell Petter, Richland Wayne Tester, Arthur F. Kluge, Hormoz Mazdiyasni, William Frederick Westlin, III, Deqiang Niu, Lixin Qiao
  • Patent number: 8338088
    Abstract: The present disclosure provides methods for assessing the glycosylation of a target glycoprotein produced by a cell through analysis of cell-surface glycans on the cell. The present disclosure therefore teaches that glycosylation of cell surface proteins can serve as a proxy for glycosylation of other proteins.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: December 25, 2012
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Brian Edward Collins, Carlos J. Bosques, Xiangping Zhu, Dorota A. Bulik, Lakshmanan Thiruneelakantapillai, Ian Christopher Parsons, Zachary Shriver, Rajeev Chillakuru, Ganesh Venkataraman
  • Patent number: 8329901
    Abstract: The present invention provides 4,6-disubstituted pyrimidine compound useful as kinase inhibitors, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: December 11, 2012
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Juswinder Singh, Shomir Ghosh, Arthur F. Kluge, Russell C. Petter, Richland W. Tester
  • Patent number: 8329455
    Abstract: This invention relates generally to systems and methods for digestion of solid waste that simplify solids handling. In certain embodiments, anaerobic methane extraction takes place for a period of time (e.g., from 1 to 4 weeks), after which an aerobic composting process begins in the same chamber. The organic waste remains in place and oxygen (e.g., in air) is forced into the chamber for an additional period of time (e.g., from 2 to 4 weeks). At the conclusion of the aerobic phase, the process yields a rough compost product that is stable and pathogen free. The rough compost can be further processed and blended to create high value engineered soils.
    Type: Grant
    Filed: September 6, 2011
    Date of Patent: December 11, 2012
    Assignee: Aikan North America, Inc.
    Inventor: Christian B. Christensen
  • Patent number: 8323971
    Abstract: This invention relates to the culture of pluripotent cells in a fully humanised chemically defined medium. Cells may be cultured over a prolonged period of time without losing their pluripotent status or may be controllably induced to differentiate into progenitor cells of the three primary germ layers by the addition of differentiation factors, for example differentiation factors which modulate one or more of the Activin/Nodal, FGF, Wnt or BMP signalling pathways.
    Type: Grant
    Filed: November 9, 2007
    Date of Patent: December 4, 2012
    Assignee: Cambridge Enterprise Limited
    Inventors: Roger Pedersen, Ludovic Vallier
  • Patent number: 8324284
    Abstract: The present invention provides compounds having formula (I): and additionally provides methods for the synthesis thereof, compositions thereof, and methods for the use thereof in the treatment of various disorders including cancer, metastasis and disorders involving increased angiogenesis, wherein R1-R6, Ra-Rc, Q, Y1, Y2 and n are as defined herein.
    Type: Grant
    Filed: May 12, 2011
    Date of Patent: December 4, 2012
    Assignee: Sloan-Kettering Institute for Cancer Research
    Inventors: Samuel J. Danishefsky, Christoph Gaul, Jon T. Njardarson
  • Patent number: 8322532
    Abstract: Packaging device (10, 10?, 10?) for packaging at least one object (12, 12?, 12?), that is essentially flat, in particular a valuable technical object, such as a lithium-ion cell, including: a bottom plate (14) having at least one first side rim (42), which is linear in regard to at least a part thereof, and at least one first cover plate (20) having at least one first side rim (46) which is linear in regard to at least one part thereof, which is hingeably linked to the first side rim (42) of the bottom plate (14) such that the cover plate (20) can be hinged between a closed position in which the cover plate at least partially covers the bottom plate, and an open position in which the cover plate is not opposite to the bottom plate, characterized in that the bottom plate (14) or the at least one cover plate (20) comprises on one side a cushioning layer (16, respectively 22), wherein the cushioned side faces the object (12, 12?, 12?) when said object is in the packaging and the at least one cover plate (20) is
    Type: Grant
    Filed: October 23, 2009
    Date of Patent: December 4, 2012
    Inventors: Tim Schafer, Andreas Gutsch, Gunter Eichinger, Claus-Rupert Hohenthanner, Christian Junker, Magnus Mickel, Heike Schone
  • Patent number: 8318206
    Abstract: The present invention provides a particle aggregate comprising particles linked to other particles via linkers that are capable of being cleaved by an enzyme. The particles may be linked directly to other particles by the linkers or may be linked indirectly by means of a binding moiety. The invention also provides a particle coupled to a binding moiety via a linker that can be cleaved by an enzyme. The present invention may be used in diagnosing a disease or condition associated with the enzyme, or may be used to treat such a disease or condition whereby the drug is retained in the particle aggregate until the linkers are cleaved by the enzyme.
    Type: Grant
    Filed: November 29, 2006
    Date of Patent: November 27, 2012
    Assignee: Imperial Innovations Limited
    Inventors: Molly M. Stevens, Rein Ulijn, Anna Sague Laromaine, Liling Koh
  • Patent number: 8313894
    Abstract: Methods and compositions for identifying antigens of human lymphocytes are provided herein.
    Type: Grant
    Filed: July 1, 2009
    Date of Patent: November 20, 2012
    Assignee: Genocea Biosciences, Inc.
    Inventors: Jessica Flechtner, Todd Gierahn
  • Patent number: 8313756
    Abstract: Urea compositions useful for treatment of dermatological conditions. The compositions may include greater than about 50 wt-% urea, and methods of making such compositions are provided.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: November 20, 2012
    Assignee: Fougera Pharmaceuticals, Inc.
    Inventors: Ralph N. Landau, Dale R. Sanson, Amir Kamyar Jahani
  • Patent number: 8309653
    Abstract: Water-based coatings having writable-erasable surfaces are provided. The coatings have many desirable attributes. For example, the coatings cure under ambient conditions, have low or no VOC emissions during and upon curing, and have reduced tendency to form ghost images, even after prolonged normal use.
    Type: Grant
    Filed: January 9, 2009
    Date of Patent: November 13, 2012
    Assignee: IdeaPaint, Inc.
    Inventors: John Goscha, Martin Douglas Donbrosky, Jr.
  • Patent number: 8312505
    Abstract: An electronic card connector is used to connect an electronic card to an electronic device, such as a level-shifting device. The electronic card connector includes an insert slot unit and a switch unit. The insert slot unit is adapted for insertion of the electronic card and is provided with a power signal terminal for providing electric power to the electronic card that is inserted into the insert slot unit. The 10 switch unit is disposed in the insert slot unit, is operable to establish electrical connection between the power signal terminal and a first power source when the electronic card inserted into the insert slot unit does not actuate the switch unit, and is further operable to establish electrical connection between the power signal terminal and a second power source when the electronic card inserted into the insert slot unit actuates the switch unit.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: November 13, 2012
    Assignee: Wistron Corporation
    Inventors: Pi-Chang Chiu, Kuo-Hua Chen
  • Patent number: 8309685
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: July 2, 2009
    Date of Patent: November 13, 2012
    Assignee: Celgene Avilomics Research, Inc.
    Inventors: Russell C. Petter, Juswinder Singh, Arthur F. Kluge, Deqiang Niu, Lixin Qiao, Shomir Ghosh
  • Patent number: 8309570
    Abstract: Central neuropathic pain is treated with an analgesic composition that consists essentially of an N-methyl-D-aspartate (NMDA) receptor antagonist. In one embodiment, the invention includes chronic administration of the (NMDA) receptor antagonist. In another embodiment, the invention is use of an NMDA receptor antagonist or component thereof for the manufacture of a medicament than includes an analgesic component that consists essentially of an NMDA receptor antagonist for the chronic treatment of central neuropathic pain.
    Type: Grant
    Filed: June 7, 2001
    Date of Patent: November 13, 2012
    Assignee: Analgesic Neuropharmaceuticals, LLC
    Inventor: Christine Nai-Mei Sang
  • Patent number: 8304250
    Abstract: A multi-dimensional chromatographic method for the separation of N-glycans. The method comprises providing a glycan preparation that includes at least one negatively charged N-glycan. The glycan preparation is then separated by anion-exchange chromatography and at least one secondary chromatographic technique.
    Type: Grant
    Filed: April 15, 2008
    Date of Patent: November 6, 2012
    Assignee: Momenta Pharmaceuticals, Inc.
    Inventors: Ian Christopher Parsons, Ting Zheng, Nur Sibel Gunay, Carlos J. Bosques
  • Patent number: RE43823
    Abstract: Compositions are provided that comprise antibody against coreceptors for human immunodeficiency virus such as CCR5 and CXCR4. In particular, monoclonal human antibodies against human CCR5 are provided that bind to CCR5 with high affinity and are capable of inhibiting HIV infection at low concentrations. The antibodies can be used as prophylactics or therapeutics to prevent and treat HIV infection, for screening drugs, and for diagnosing diseases or conditions associated with interactions with HIV coreceptors.
    Type: Grant
    Filed: November 18, 2011
    Date of Patent: November 20, 2012
    Assignee: Genetastix Corporation
    Inventors: Shaobing Hua, Michelle Haynes Pauling, Li Zhu